Related Experiment Video
Updated: Jun 22, 2025

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Lung Diseases and Rare Disorders: Is It a Lysosomal Storage Disease? Differential Diagnosis, Pathogenetic Mechanisms
Chiara Montanari1,2, Veronica Maria Tagi1,2, Enza D'Auria1,2
1Department of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, 20154 Milan, Italy.
Insights
Pediatric pulmonologists can diagnose rare lysosomal storage diseases (LSDs) by recognizing respiratory symptoms. Early diagnosis and treatment of LSDs are crucial for managing lung function and preventing further damage.
Area of Science:
- Pediatric Pulmonology
- Rare Genetic Diseases
- Lysosomal Storage Diseases (LSDs)
Background:
- Lysosomal storage diseases (LSDs) are genetic disorders caused by enzyme deficiencies, leading to substrate accumulation and organ damage.
- Respiratory impairment in LSDs can manifest with restrictive or obstructive patterns due to skeletal, bronchial, interstitial, or muscular involvement.
- Underdiagnosis of less severe LSD forms can occur, particularly when presenting later in childhood.
Purpose of the Study:
- To review pulmonary manifestations and diagnostic approaches for treatable LSDs in children.
- To guide pediatric pulmonologists in differentiating LSDs based on respiratory findings, radiological signs, and symptoms.
- To discuss follow-up strategies and the impact of novel therapies on lung involvement in LSDs.
Main Methods:
- This narrative review synthesizes current literature on pulmonary aspects of LSDs.
- Key elements for differential diagnosis of specific LSDs (Gaucher disease, ASM deficiency, Pompe disease, MPS) are outlined.
- Radiological findings, lung function patterns, and associated symptoms are discussed.
Main Results:
- Respiratory symptoms in LSDs vary depending on the affected tissues and substrate accumulation.
- Pulmonary involvement can present as restrictive (bone/muscle) or obstructive (bronchial) patterns.
- Timely diagnosis and intervention, including new therapies, can improve lung function and outcomes.
Conclusions:
- Pediatric pulmonologists play a key role in identifying and managing LSDs through careful clinical evaluation and diagnostic workup.
- Recognizing overlapping respiratory features is essential for differential diagnosis in children with suspected LSDs.
- Effective management of LSDs, particularly with early treatment, can mitigate or improve pulmonary complications.
Abstract:
Pulmonologists may be involved in managing pulmonary diseases in children with complex clinical pictures without a diagnosis. Moreover, they are routinely involved in the multidisciplinary care of children with rare diseases, at baseline and during follow-up, for lung function monitoring. Lysosomal storage diseases (LSDs) are a group of genetic diseases characterised by a specific lysosomal enzyme deficiency. Despite varying pathogen and organ involvement, they are linked by the pathological accumulation of exceeding substrates, leading to cellular toxicity and subsequent organ damage. Less severe forms of LSDs can manifest during childhood or later in life, sometimes being underdiagnosed. Respiratory impairment may stem from different pathogenetic mechanisms, depending on substrate storage in bones, with skeletal deformity and restrictive pattern, in bronchi, with obstructive pattern, in lung interstitium, with altered alveolar gas exchange, and in muscles, with hypotonia. This narrative review aims to outline different pulmonary clinical findings and a diagnostic approach based on key elements for differential diagnosis in some treatable LSDs like Gaucher disease, Acid Sphingomyelinase deficiency, Pompe disease and Mucopolysaccharidosis. Alongside their respiratory clinical aspects, which might overlap, we will describe radiological findings, lung functional patterns and associated symptoms to guide pediatric pulmonologists in differential diagnosis. The second part of the paper will address follow-up and management specifics. Recent evidence suggests that new therapeutic strategies play a substantial role in preventing lung involvement in early-treated patients and enhancing lung function and radiological signs in others. Timely diagnosis, driven by clinical suspicion and diagnostic workup, can help in treating LSDs effectively.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
07:17Author Spotlight: Studying Spatial Protein Expression Using Agarose Embedded Lung Tissue Sections
Published on: October 6, 2023
Related Concept Videos
Lysosomal Hydrolases
Cystic Fibrosis: Management
Sinus disease and chronic...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Other Pulmonary Disorders